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In the emerging ﬁeld of synthetic biology, scientists are focusing on designing and creating func-
tional devices, systems, and organisms with novel functions by engineering and assembling stand-
ardised biological building blocks. The progress of synthetic biology has signiﬁcantly advanced the
design of functional gene networks that can reprogrammetabolic activities in mammalian cells and
provide new therapeutic opportunities for future gene- and cell-based therapies. In this review, we
describe the most recent advances in synthetic mammalian gene networks designed for biomedical
applications, including how these synthetic therapeutic gene circuits can be assembled to control
signalling networks and applied to treat metabolic disorders, cancer, and immune diseases. We con-
clude by discussing the various challenges and future prospects of using synthetic mammalian gene
networks for disease therapy.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The rapid development of molecular biology and bioinformat-
ics, has enabled the rational, systematic design and creation of bio-
logical networks with desired functionality that do not exist in
nature [1–3]. This emerging ﬁeld is referred to as synthetic biology,
which is deﬁned as the science of the design and construction of
novel functional devices, systems, and even organisms by applying
engineering and computational principles [4,5]. In the relatively
early stages of synthetic biology, many complex synthetic gene
regulatory circuits were designed and created in prokaryotes or
lower eukaryotes, including toggle switches [6], oscillators [7–9],
timers [10], counters [11], clocks [12], pattern detectors [13],
band-pass ﬁlters [14], and intercellular communication systems
[15,16]. The development of these pioneering devices has given
rise to various therapeutic possibilities for synthetic biology.
Examples include designing a bacteriophage to switch off the bac-
terial SOS DNA repair system [17], engineering bacteria or viruses
for cancer-targeting therapy [18–23], engineering Escherichia coli
to prevent cholera infection [24], and engineering yeast cells to
produce the precursor of the antimalarial drug artemisinic acid
[25]. Although it is relatively simple to engineer synthetic thera-
peutic circuits in prokaryotic systems, the clinical applications ofthese prokaryotic synthetic systems are limited. Therefore, increas-
ing numbers of studies have focused on the design of mammalian
transgene control devices that form the basis for the assembly of
synthetic therapeutic networks in mammalian cells. Most of these
control devices are designed to respond to small molecule chemi-
cals [26–33]. Recently, more elegant circuits were developed to use
traceless inducers such as light and radio waves to regulate trans-
gene expression [34–36]. Furthermore, in the latest studies, several
gene networks were created to monitor pathological levels of
metabolites in the body, such as uric acid, fatty acids, bile acids,
and dopamine [31,32,37,38]. These pioneering studies have
opened a door for the development of new strategies to treat
human diseases (Fig. 1). This review highlights the latest state-
of-the-art synthetic gene circuits and prototype treatment strate-
gies for therapeutic purposes.
2. Synthetic gene circuits for the treatment of metabolic
disorders
2.1. Combating diabetes
Type 2 diabetes is a rapidly rising global epidemic characterised
by islet beta-cell dysfunction, insulin resistance, and high blood
glucose level [39,40]. It is a worldwide medical condition causing
mortality in both developing and developed countries. The
currently available therapeutic strategies include daily insulin
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Fig. 1. The engineering principles of designed gene circuits for disease therapy in mammalian synthetic biology. Synthetic biologists capitalise on naturally existing
biomolecules, including functional DNA, RNA, and proteins from a range of organisms such as microbes, plants, and mammals. These valuable biomolecules have been
biochemically studied and are well understood. By using engineering principles, synthetic biologists design and reassemble these standard basic biobricks in a rational way to
engineer state-of-the-art therapeutic gene circuits, which are then engineered into microencapsulated mammalian cell implants. These engineered cell implants can be
transplanted into mouse models of disease and are regulated to produce therapeutic proteins to treat diseases.
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control [41].
Recently, two promising synthetic biology-based therapeutic
strategies were developed for the treatment of diabetes. The ﬁrst
case is the design and construction of an optogenetic gene circuit
to maintain blood glucose homeostasis [34]. This pioneering study
by Ye et al. [34] used blue light as a traceless, molecule-free trigger
signal to regulate transgene expression in animals. In this design,
melanopsin is ectopically expressed in HEK-293 cells and used as
a light receptor. Upon illumination, melanopsin signalling leads
to elevated intracellular calcium levels and the cellular response
to this is rewired to promote calcium-mediated activation of the
transcription factor NFAT (nuclear factor of activated T cells). This
signalling cascade leads to the activation the PNFAT promoter and
expression of the glucagon-like peptide 1 (GLP-1), a peptide hor-
mone that can restore blood glucose homeostasis in type 2 diabe-
tes. Engineered cells containing this synthetic circuit were
encapsulated in immunoprotective microcontainers and implanted
into a type 2 diabetic mouse model. Upon blue-light illumination,
the treated animals exhibited improved blood-glucose homeosta-
sis (Fig. 2a). The utilisation of light as a trigger signal to regulate
insulin expression for the treatment of diabetes was independently
conﬁrmed by another study [42].
Another study performed by Stanley et al. used radio waves as a
trigger signal to control insulin expression and maintain blood glu-
cose homeostasis in diabetic mice [35]. In this system, a tempera-
ture-sensitive receptor, TRPV1, is antibody-coated with iron-oxide
nanoparticles and triggers a calcium surge when heated by radio
waves. Calcium signalling is rewired to promote calcium-mediated
activation of insulin expression. Mice with transplanted tumour
xenografts containing this synthetic circuit were exposed to radio
waves, which activated the expression and release of insulin from
the tumours and, therefore, lowered blood glucose levels in the
diabetic mice [35].
2.2. Treating the metabolic syndrome
Metabolic syndrome is a primary, epidemic public health chal-
lenge in the 21st century that is characterised by the three inter-
linked and interdependent metabolic disorders of hypertension,
hyperglycemia, and obesity [43,44]. The currently available thera-
peutic strategy is to identify and treat each metabolic disorder and
risk factor independently [41]. Until now, there has been no well-
coordinated therapeutic strategy.
Recently, Ye et al. developed a multifunctional synthetic gene
circuit for simultaneously treating multiple risk factors of meta-
bolic syndrome [45] (Fig. 2b). The combination of drug and genetherapies may improve the chances of clinical success. Guanabenz
is a clinically approved antihypertensive drug that shows agonistic
effects on the trace amine receptor 1 cTAAR1, whose activation
triggers a strong cAMP second messenger response in mammalian
cells. Therefore, the pharmacodynamics of guanabenz was func-
tionally rewired via the signal transduction pathway of cTAAR1
to initiate transgene expression through the activation of CREB1
mediated by a cAMP-dependent phosphokinase A (PKA). Transcrip-
tion initiation is driven by a synthetic promoter containing CREB1-
speciﬁc, cAMP-response elements. Thus, this synthetic gene net-
work enables guanabenz to dose-dependently control the expres-
sion of a fusion hormone GLP-1-Fc-Leptin, which simultaneously
attenuates hypertension (guanabenz), hyperglycaemia (GLP-1),
and obesity (Leptin) in mice with metabolic syndrome.
2.3. Maintaining uric acid homeostasis
Uric acid is the end-product of purine metabolism in mammals,
and its homeostasis can be disrupted by many factors, leading to
hyperuricemia and associated pathologies including the tumour
lysis syndrome and gout [46,47].
A synthetic biology-based prosthetic network was designed to
sense and monitor host metabolic parameters and respond accord-
ingly to reverse the risk factors. Kemmer et al. developed a type of
sensor–effector prosthetic network to sense the uric acid concen-
trations in the blood and control the expression of a secretion-
engineered urate oxidase (smUOX) accordingly, which can restore
urate homeostasis [31] (Fig. 2c). In this network design, smUOX
expression dynamics are regulated by a bacterial HucR repressor,
which is fused to the transcriptional-silencing domain KRAB
(KRAB–HucR). Upon binding to its cognate operator, KRAB–HucR
inhibits smUOX expression. However, when uric acid binds to
HucR–KRAB and disrupts the binding of HucR–KRAB to its opera-
tor, smUOX is derepressed and secreted into the bloodstream
where it converts urate into allantoin that is eliminated by renal
clearance. Engineered cells containing this synthetic device were
implanted into a mouse model of acute hyperuricemia. This syn-
thetic device was able to stimulate the production of smUOX to
dissolve uric acid crystal deposits in the kidneys of the mice and
restore blood urate homeostasis [31].
2.4. Treating obesity
Diet-induced obesity (DIO) is a lifestyle-associated medical con-
dition that results from excessive food energy intake, lack of phys-
ical activity, and genetic predisposition [48]. Obesity can increase
the risk of developing a wide range of associated diseases, such
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Fig. 2. Synthetic gene circuits designed for disease therapy. (a) A synthetic optogenetic transcription device for controlling blood-glucose homeostasis in diabetic mice. Upon
blue-light illumination the ectopically expressed G-protein-coupled receptor (GPCR) melanopsin is activated and sequentially activates phospholipase C (PLC) through Gaq,
and phosphokinase (PKC), which then triggers calcium inﬂux through the activation of transient receptor potential channels (TRPCs) and from the endoplasmic reticulum
(ER). The elevated intracellular calcium levels activate calmodulin (CaM) and then calcineurin (CaN), which in turn activates the transcription factor NFAT (nuclear factor of
activated T cells) by dephosphorylation. The activated NFAT translocates into the nucleus, binds to its speciﬁc promoter (PNFAT), and initiates expression of glucagon-like
peptide-1 (GLP-1). The engineered HEK-293 cells incorporating this synthetic gene circuit were microencapsulated and subcutaeneously implanted into diabetic mice. Upon
external illumination of the mice by blue light, the synthetic gene circuit was activated and lowered the blood-glucose levels in the diabetic mice. (b) A pharmaceutically
controlled designer circuit for the treatment of metabolic syndrome. Binding of guanabenz to the ectopically expressed chimeric G-protein-coupled trace-amine-associated
receptor (cTAAR1) activates adenylyl cyclase through Gas, which converts ATP into cAMP. The intracellular cAMP surge is rewired to activate the cAMP-dependent
phosphokinase A (PKA), which in turn activates the cAMP-response element-binding protein 1 (CREB1). Activated CREB1 binds to its synthetic promoter (PCRE) and drives
expression of the chimeric hormone protein GLP-1-Fc-Leptin. Mice with metabolic syndrome that were treated with guanabenz and implanted with the designer cells
containing this synthetic circuit showed attenuated hypertension (guanabenz), hyperglycaemia (GLP-1), as well as dyslipidaemia and obesity (both Leptin). (c) Self-sufﬁcient
synthetic circuits control blood-urate homeostasis in mice. The heterologous expression of a urate transporter is able to increase the intracellular urate levels in designer cells.
A uric acid sensor KRAB-HucR is designed to detect urate levels and can inhibit the transcription of the secreted urate oxidase variant (smUOX) by binding to its synthetic
promoter (PhucO8). When the urate concentration reaches pathological levels, the uric acid binds to KRAB-HucR, which is then released from PhucO8 and eventually triggers the
expression of smUOX. smUOX lowers the blood-urate levels by converting urate into allantoin. (d) A closed-loop synthetic fatty-acid-controlling mammalian gene circuit for
correcting obesity in mice. This synthetic fatty acid-responsive transcription circuit consists of a hybrid LSR, a fusion protein combining the phloretin-triggered repressor
(TtgR) and the ligand-binding domain of the human peroxisome proliferator-associated receptor alpha (PPARa), that can speciﬁcally bind to the TtgR-speciﬁc operator linked
to a minimal promoter (PhCMVmin) to regulate transgene expression. In the absence of fatty acids, LSR associates with endogenous co-repressors to inhibit expression of the
appetite-suppresing peptide hormone pramlintide. In the presence of fatty acids, LSR associates with endogenous co-activators to initiate pramlintide expression. The
transgene expression can also be turned off by adding phloretin, which disrupts LSR-promoter binding. Mice with diet-induced obesity (DIO) implanted with
microencapsulated designer cells containing this synthetic circuit demonstrated a signiﬁcant reduction in food consumption, blood lipid levels, and body weight. (e) Synthetic
bile acid-regulated OFF and ON switches. The OFF switch: the transcriptional repressor CmeR was fused to the Herpes simplex-derived transactivation domain (VP16) to obtain
a bile acid-dependent transactivator, CmeA1 (CmeR-VP16), driven by the simian virus 40 promoter (PSV40). In the absence of bile acids (BA), CmeA1 binds to its chimeric
promoter PCmeOFF, composed of a CmeR-speciﬁc operator module and a minimal version of the human cytomegalovirus immediate early promoter (PhCMVmin), and activates
SEAP expression. In the presence of BA, CmeA1 dissociates from PCmeOFF and the SEAP expression is switched off. The ON switch: CmeR is fused to the human Kruppel-
associated box (KRAB) domain to obtain a BA-dependent transsilencer, CmeA2 (CmeR-KRAB), that drives expression from the PCmeON promoter. In the absence of BA, CmeA2
binds to its speciﬁc tandem operator sites (OCme) and inhibits PSV40 driving SEAP expression. In the presence of BA, CmeA2 is released from PCmeON resulting in SEAP
expression. (f) A synthetic reward-based dopamine-triggered signalling network for controlling blood pressure in hypertensive mice. The binding of dopamine to the
heterologously expressed human dopamine receptor 1 (DRD1) activates adenylyl cyclase through Gas, which catalyses ATP into cAMP. The intracellular cAMP surge is
rewired to activate PKA, which in turn activates CREB1. Activated CREB1 binds to its synthetic promoter (PCRE) and drives expression of the blood pressure-reducing atrial
natriuretic peptide (ANP). When hypertensive mice were implanted with this synthetic sensor–effector device and their reward system was triggered by sexual arousal, the
treated mice showed a signiﬁcant increase in dopamine and blood ANP levels and decrease in blood pressure.
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tain types of cancer. It is becoming one of the most widespread epi-
demic diseases, affecting up to 1.5 billion people in developing as
well as developed countries [49–51].
Recently, Roessger et al. designed a closed-loop genetic circuit
that can constantly monitor blood fatty acid levels in DIO mice
and express accordingly the clinically licensed appetite-suppress-
ing peptide hormone pramlintide to reverse hyperlipidaemia and
obesity in the animals [37] (Fig. 2d). In this synthetic gene circuit,
pramlintide expression levels are controlled by the lipid-sensing
receptor (LSR), a hybrid transcription factor, containing the
ligand-binding domain of PPARa and the bacterial DNA-binding
repressor TtgR, showing dual-input sensitivity to fatty acids as well
as the apple metabolite and cosmetic additive phloretin. In the
absence of fatty acids, LSR recruits co-repressors and inhibits PTtgR-
driven transgene expression. In the presence of fatty acids co-acti-
vators bind to LSR, and the PTtgR promoter starts to express pram-
lintide in a dose-dependent manner. However, in the presence of
phloretin, LSR is released from PTtgR and transcription is turned
off irrespective of the lipid status of the cells. Hence, the TtgR com-
ponent of the lipid-sensor ensures promoter speciﬁcity and also
provides a potential safety switch to override lipid-dependent pro-
moter activation. Engineered cells containing this synthetic circuit
were implanted into wild-type mice fed with diets containing dif-
ferent amounts of fat. This resulted in diet-dependent expression
of pramlintide, which suppresses appetite, promotes satiety, and
slows gastric emptying, therefore limiting food intake, attenuating
the hyperlipidaemic blood levels and restoring the body weight of
treated mice [37].
Because obesity is associated with high serum levels of bile
acids [52–54], Roessger et al. also designed and created a bile-
acid-controlled transgene expression circuit in mammalian cells
[32]. This synthetic metabolite-triggered gene circuit is also able
to interface with the host metabolism and appropriately control
transgene expression in mice (Fig. 2e). By fusing the bile-acid-
dependent transcriptional repressor CmeR to different transactiva-
tion and trans-silencing domains, the authors created a bile-acid-
sensitive OFF (BEAROFF) and ON switch (BEARON). The BEAROFF cir-
cuit contains the bile-acid-dependent transactivator CmeA1
(CmeR-VP16), which was assembled by fusing CmeR to the VP16
transactivation domain, and a cognate promoter (PCmeOFF). HEK-
293 cells cotransfected with the CmeA1 expression vector and
the CmeA1-speciﬁc PCmeOFF-driven SEAP reporter vector were trea-
ted with increasing concentrations of cholic acid and exhibited
dose-dependent repression of SEAP expression. The BEARON switch
consists of the bile acid-dependent trans-silencer CmeA2, which
was assembled by fusing CmeR to the human Krueppel-associated
box (KRAB) trans-silencing domain, and a CmeA2-speciﬁc PCmeON
promoter. HEK-293 cells cotransfected with the CmeA2 expression
vector and the PCmeON-driven SEAP reporter vector exhibited dose-
dependent induction of SEAP expression. The BEARON gene switch
was further validated in mice, which veriﬁed that it could induce
SEAP expression in animals treated with bile acids [32].
2.5. Controlling blood pressure
Dopamine is a key endogenous neurotransmitter that coordi-
nates learning, controls emotions, and promotes reward- and plea-
sure-seeking behaviour [55–57]. Excessive reward-seeking
behaviour may lead to addiction, drug abuse, schizophrenia,
depression or obesity [58,59]. The pleasure status directly corre-
lates with the dopamine levels released in the brain. Since dopa-
mine leaks into bloodstream via the sympathetic nervous system,
brain and blood dopamine levels are interrelated. Capitalizing on
this correlation between brain and blood dopamin levels, Roessger
et al. designed and created a synthetic dopamine-responsivesensor–effector device that can monitor dopamine levels in the
peripheral circulation and remotely control transgene expression
in a dose-dependent manner [38]. This synthetic dopamine sen-
sor–effector circuit can interface with reward-associated brain
activities to regulate the clinically licensed atrial natriuretic pep-
tide (ANP) for the treatment of hypertension. The dopamine sen-
sor–effector circuit was designed to utilise ectopically expressed
human dopamine receptor D1, whose native signalling cascade
was rewired to induce cAMP-dependent protein kinase A (PKA)-
mediated phosphorylation of cAMP response element-binding pro-
tein (CREB1), which can trigger ANP expression from synthetic pro-
moters containing CREB1-speciﬁc operators (PCRE). To conﬁrm
reward-triggered ANP expression in vivo, hypertensive mice
implanted with microencapsulated HEK-293 cells transgenic for
the dopamine-sensitive ANP expression were exposed to reward-
triggering sexual arousal. Sexual arousal induced dopamine release
and dopamine-dependent ANP expression, which reversed the
hypertonic systolic blood pressure of the treated animals to normal
levels (Fig. 2f).
3. Synthetic gene circuits for anti-cancer therapy
3.1. An AND logic-gated cancer kill switch
Cancer encompasses a large group of diseases characterised by
uncontrolled cellular proliferation [60]. The abnormal cells can
invade nearby healthy tissues and spread to other organs [60]. Can-
cer is one of the most important human diseases; therefore, a
broad array of research has focused on ﬁnding new targets or ther-
apies for the treatment of cancer. However, one of the key chal-
lenges for cancer therapy is to eliminate cancer cells without
damaging the surrounding healthy tissues [60]. The most recent
advances in cancer-targeting therapies include the engineering of
oncolytic viruses [20,61], tumour-targeting bacteria [21–23], and
synthetic cancer cell-speciﬁc kill switches [62–64].
Nissim et al. developed a dual-promoter integrator that can pre-
cisely discriminate and kill cancer cells [62]. Two different tumour-
speciﬁc promoters drive the expression of two chimeric proteins
(DocS-VP16 and Coh2-GAL4). Only when both of the two chimeric
proteins are simultaneously expressed in response to cancer-indi-
cating signals, do they dimerise to form a functional transactivator
(GAL4-Coh2-DocS-VP16) that activates the PGAL4 promoter to trig-
ger the expression of the Herpes simplex-derived thymidine kinase
(HSV-TK). HSV-TK converts the prodrug ganciclovir to a toxic
derivative, resulting in targeted cancer cell death (Fig. 3a). This
synthetic dual-promoter circuit works as a digital-like AND logic
gate that can improve targeting precision and efﬁcacy in cancer
cells.
3.2. A multi-input microRNA-based cancer classiﬁer
In another study performed by Xie et al., a cancer-cell classiﬁer
was developed to identify HeLa-speciﬁc endogenous microRNA
concentrations [63] (Fig. 3b). This multi-input classiﬁer consists
of a combination of genetic sensors that detect high and low levels
of speciﬁc sets of microRNAs. If the expression of the speciﬁc input
microRNAs matches a pre-deﬁned high or low level proﬁle, the
cancer classiﬁer drives expression of the pro-apoptotic hBax, which
kills cancer cells such as HeLa. In the high microRNA sensor, high
levels of speciﬁc microRNAs (microRNA-17 microRNA-21 and
microRNA-30a) prevent the expression of the reverse tetracy-
cline-dependent transactivator (rtTA) and the lactose operon
repressor (LacI) in a two-level cascade which results in derepres-
sion of hBax transcription. In the low microRNA sensor, hBax
expression is only permitted by low levels of a second set of
speciﬁc microRNAs (microRNA-141, microRNA-142(3p), and
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containing minigene. Upon permissive splicing HSV-TK is expressed which kills the cell in the presence of the prodrug ganciclovir. (d) A synthetic RNA switch controlling T-
cell proliferation. CTLL-2 cells were reprogrammed to proliferate in response to the external trigger molecule theophylline. The proliferation of CTLL-2 cells requires the
presence of interleukin 2 (IL-2). The theophylline-dependent hammerhead ribozyme was engineered into the 30-UTR of IL-2. The addition of theophylline inhibits the
ribozyme self-cleavage and allows IL-2 translation which induces proliferation of the CTLL-2 cells. (e) Synthetic signalling cascades for chronic lymphocytic leukemia
treatment. The chimeric antigen receptor (CAR) contains four different domains: an anti-CD19 single chain fragment, a CD8a-derived transmembrane domain, a human
CD137-derived co-stimulatory domain, and a CD3f signalling domain. Patient-derived T cells were transduced with CAR-encoding lentiviral particles and reinfused into the
patient. CD19-positive cancer cells were recognized by CAR-transgenic T cells which resulted in expansion of the engineered T-cell population and killing of the tumor cells.
(f) Controlling human T-cell response by rewiring kinase pathways with bacterial effectors. A synthetic amplitude limiter or a synthetic pause switch was designed to control
cytokine release in isolated primary human CD4+ T cells. The synthetic pause switch was created by expressing YopH or OspF, which can inhibit speciﬁc steps in the T-cell
receptor (TCR) signalling pathway. Doxycycline controls the expression of bacterial effectors (YopH and OspF), which are driven by a tetracycline-inducible promoter. The
extracellular signal-regulated kinase (ERK), a key component of TCR signalling, could be inactivated by OspF, whereas the T-cell scaffold protein LAT could be
dephosphorylated by YopH. Therefore, T-cell activation is controlled by externally added doxycycline.
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microRNA-142(3p) and microRNA-146a, and the presence of
microRNA-17, microRNA-21, and microRNA-30a, this cancer
classiﬁer can induce apoptosis through production of the hBax
protein. By integrating the intracellular levels of microRNAs, this
synthetic logic decision-making circuit is able to speciﬁcally kill
cancer cells [63].3.3. A synthetic protein-sensing RNA-based cancer-killing switch
Culler et al. developed a synthetic protein-sensing RNA actua-
tion device that autonomously detects and speciﬁcally kills cancer
cells [64]. The device consists of a synthetic three-exon-two-intron
minigene that contains aptamers speciﬁc for neoplastic markers
(e.g., NF-jB or b-catenin) and controls functional splicing of the
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of the neoplastic markers to the embedded aptamers of the HSV-
TK-encoding transcript triggers speciﬁc splicing, expression of
HSV-TK and results in HSV-TK-mediated cell-killing in the pres-
ence of the prodrug ganciclovir (Fig. 3c). This RNA switch only
works as a cell-killing switch in the presence of endogenous cancer
markers, while leaving the surrounding healthy tissue unharmed.
The engineering of mammalian cells to perform logic calculations
according to the presence or absence of speciﬁc cancer biomarkers
is a promising option that may have great potential for more pre-
cise cell-based therapies in the future.
4. Synthetic gene circuits for immune-mediated therapy
4.1. A synthetic riboswitch controlling T-cell proliferation
T cells are a class of white blood cells that are essential to the
mammalian immune system, especially the response to and
defence against invasive pathogens and cancer cells [65–68].
Because human T cells can be easily isolated from patients, genet-
ically engineered, and then returned into patients to treat cancer or
chronic infection, they have great value for synthetic biologists as
platforms for engineering therapeutic gene circuits [65,66,69].
One example is a synthetic RNA control switch constructed to
externally control T-cell proliferation in mice [70] (Fig. 3d). In this
study, the authors designed a synthetic ribozyme switch that
enables programmable, drug-controlled expression of IL-2, a cyto-
kine that is known to trigger proliferation of antigen-stimulated T
cells. This was achieved by using a theophylline-responsive ham-
merhead ribozyme located in the 30-UTR of the IL-2 gene. When
engineered into T cells and reinfused into mice, the animals’ T-cell
population could be expanded by the administration of theophyl-
line [70].
4.2. Engineering of T cells for tumour therapy
Another example is the reprogramming of T cells for tumour
immunotherapy [69]. Porter et al. created a synthetic signalling
cascade for chronic lymphocytic leukaemia therapy. In this study,
the chimeric antigen receptor (CAR) was designed by assembling
four different functional domains: an anti-CD19 single chain frag-
ment, a CD8a-derived transmembrane domain, a human CD137-
derived co-stimulatory domain, and a CD3f signalling domain. Pri-
mary human T cells were isolated from the patient and engineered
to express the CAR. The engineered T cells were then returned into
the patient. The patients’ chronic lymphocyte leukaemia cells
expressing the CD19 marker were recognised by the transgenic T
cells expressing the chimeric antigen receptors. The transgenic T
cells were activated to proliferate, and they killed the cancer cells
[69] (Fig. 3e).
4.3. Synthetic pause switches for controlling T-cell overactivation
Engineering human T cells ex vivo and then transferring them
back into patients to treat diseases is a promising strategy. How-
ever, the therapeutic application of engineered T cells for autoim-
mune disorders has the risk of adverse side effects including the
inadvertent autoimmune-like attack of off-target host tissue
[71,72]. It is necessary to control the speciﬁcity and amplitude of
T-cell function. To balance therapeutic action and off-target toxic-
ity, bacterial virulence proteins were recently explored as a tool to
rewire kinase signalling pathways in human T cells [73] (Fig. 3f).
Isolated primary human CD4+ T cells were reengineered to regulate
cytokine release using an engineered synthetic amplitude limiter
or a synthetic pause switch. The synthetic pause switch or thesynthetic negative feedback loop was created by expressing YopH
or OspF, which can speciﬁcally inhibit the T-cell receptor (TCR) sig-
nalling pathway. A tetracycline-responsive promoter was engi-
neered to control the expression of both bacterial effectors (OspF
and YopH) by adding doxycycline. A central TCR signalling path-
way, the MAPK extracellular signal-regulated kinase (ERK) path-
way, could be inactivated by OspF, while YopH could speciﬁcally
dephosphorylate a phosphotyrosine in the T-cell scaffold protein
LAT. Therefore, T-cell activation could be externally controlled by
adding doxycycline. In this study, the authors demonstrated the
therapeutic applications of bacterial pathogen components as a
tool to design and construct feedback modulators and external
inducible pause switches, which can enable control of the T-cell
response amplitude or temporarily disable T-cell activation [73].
4.4. Remote-controlling T-cell migration by a synthetic signal
As the key players in cell-based immunity T cells are highly
motile [74–77]. Park et al. engineered T cells to speciﬁcally migrate
up a gradient of clozapine-N-oxide (CNO), an inert metabolite of
the FDA-approved antipsychotic drug clozapine. [78]. Such
remote-control of cell mobility was achieved by engineering T cells
for ectopic expression of the Di receptor, a designer receptor exclu-
sively activated by a designer drug (DREADD), which rewires to
conserved intracellular signalling and positive feedback loops that
include the activation of the Rho-family GTPase Rac and the gener-
ation of phosphatidylinositol-(3,4,5)-Tris–phosphate by phosphot-
idylinositol 3-kinase (PI3K) at the leading edge of the migrating
cells. Synthetic chemotaxis was conﬁrmed in mice where engi-
neered T cells preferentially migrated towards injected CNO-
releasing beads [78]. Synthetic remote-control of T-cell migration
may provide novel cell-based treatment strategies such as drug-
mediated T-cell trafﬁcking into tumours or to sites of infection.
5. Outlook
The engineering of gene circuits in mammalian cells has a wide
range of applications and provides new strategies for the therapeu-
tic application of synthetic biology. Recent work has led to the
design of complex synthetic mammalian gene circuits assembled
into biosensing devices that can monitor the metabolites within
or surrounding cells and offer a promising strategy for biomedical
treatment. These designed circuits are engineered to monitor,
quantify, and treat a series of diseases by detecting disease-related
speciﬁc markers and releasing a therapeutic output accordingly
through a feedback network. The precise sensing of disease signals
allows for the precise production of therapeutic molecules. The
therapeutic functions of synthetic devices have been demonstrated
by proof-of-concept studies in mouse models of human diseases
using methods such as light- or radio-wave-activated switches to
regulate the precise dosage of therapeutic hormones for diabetes
therapy [34,35]; synthetic gene networks to treat metabolic syn-
drome, obesity, and hypertension [37,38,45]; smart logic gates to
kill speciﬁc cancer cells [62,63]; and synthetic circuits to repro-
gram immune cells [69,70,73]. These pioneering studies demon-
strate the great potential of synthetic biology-based therapies to
provide novel therapeutic strategies for future clinical applications
[79,80].
In the past, synthetic biology has been focused on assembling
prokaryotic systems, and a large proportion of the available basic
biobricks have been derived from bacterial systems [26–
29,31,81–85]. Recently, receptor-based methods, especially the
G-protein-coupled receptors (GPCRs), inspired by synthetic biology
have become a promising option for therapeutic applications.
Some pioneering studies have demonstrated the great potential
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poses [30,34,37,38,45,78,86,87]. The utilization of human-derived
proteins such as GPCRs has advantages over the heterologous pro-
teins from bacterial systems because human-derived proteins can
avoid the immune response in vivo and thus improve safety for
clinical applications in the future.
Cell-based therapies are considered a very promising technique
in the next generation of medicine [74]. With the development of
synthetic biology, scientists can design and engineer versatile ther-
apeutic microbial and mammalian cells to combat different dis-
eases. However, nearly all the reported studies on the
engineering of synthetic gene circuits in mammalian cells have
been performed in cell lines, which are often utilised in mamma-
lian synthetic biology [28,31,34,38,83,84]. The challenge is to make
sure that the engineered cells containing synthetic gene networks
will have no side effects in humans. Nevertheless, microencapsula-
tion technology may become an option for the transplantation of
engineered cells into the human body for therapeutic purposes
[88]. Using this technology, engineered cells containing synthetic
therapeutic gene circuits could be sufﬁciently separated from the
rest of the tissue by a semipermeable (e.g., alginate–polylysine–
alginate) membrane that allows free communication with the body
ﬂuids and at the same time protects the cells from the body’s
immune system [89]. A pioneering clinical study conﬁrmed that
cells implanted into humans inside insulating and immunoprotec-
tive microcontainers were able to coordinate expression of thera-
peutic proteins [90]. Another way to minimise the risk is to
engineer primary cells or stem cells directly isolated from patients.
Induced pluripotent stem cell (iPSC) technology provides a way to
produce and engineer autologous cells from patients, even includ-
ing elderly patients [91]. The advantages of engineering primary
cells are obvious, including immunocompatibility and non-
carcinogenicity.
It is an ambitious goal to use synthetic-biology-based biomedi-
cal devices in the clinics. To achieve this aim, it is important to
standardise genetic circuit design and to create more robust and
higher-order genetic circuits. In the meantime, the clinical use of
synthetic therapeutic circuits will face ethical and legal issues
[92]. For now, although there are no synthetic gene circuits being
developed for the clinic or clinical trials, synthetic biologists should
design and create more reliable genetic circuits to provide evi-
dence in support of the great human therapeutic beneﬁt that could
arise from clinical trials of synthetic biology-based treatments and
to demonstrate the advantages compared with traditional thera-
peutic strategies. Despite the difﬁculties ahead, there are increas-
ing numbers of synthetic biology-related studies on the way that
will have a deep impact on the treatment strategies of the 21st
century. We believe that along with the progress that has come
from proof-of-concept studies, mammalian synthetic biology will
become a universally accepted tool for clinical medical practice
in this century.
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